BR112015025058A8 - Composição farmacêutica do tipo matriz contendo lacosamida - Google Patents

Composição farmacêutica do tipo matriz contendo lacosamida

Info

Publication number
BR112015025058A8
BR112015025058A8 BR112015025058A BR112015025058A BR112015025058A8 BR 112015025058 A8 BR112015025058 A8 BR 112015025058A8 BR 112015025058 A BR112015025058 A BR 112015025058A BR 112015025058 A BR112015025058 A BR 112015025058A BR 112015025058 A8 BR112015025058 A8 BR 112015025058A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
lacosamide
composition containing
matrix type
type pharmaceutical
Prior art date
Application number
BR112015025058A
Other languages
English (en)
Other versions
BR112015025058A2 (pt
BR112015025058B1 (pt
Inventor
Joon Lee Sang
Mo Koo Hyoung
Oh Myeongjun
Young Ko Chan
Original Assignee
Bio Pharmartis Co Ltd
Bioinnotis Co Ltd
Hyundai Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Pharmartis Co Ltd, Bioinnotis Co Ltd, Hyundai Pharm Co Ltd filed Critical Bio Pharmartis Co Ltd
Publication of BR112015025058A2 publication Critical patent/BR112015025058A2/pt
Publication of BR112015025058A8 publication Critical patent/BR112015025058A8/pt
Publication of BR112015025058B1 publication Critical patent/BR112015025058B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

COMPOSIÇÃO FARMACÊUTICA CAPAZ DE CONTROLAR FACILMENTE O PADRÃO DE DISSOLUÇÃO DE LACOSAMIDA OU DE UM SAL FARMACEUTICAMENTE ACEITÁVEL DA MESMA. A presente invenção refere-se a uma composição farmacêutica do tipo matriz contendo lacosamida, que é um princípio ativo, ou um sal farmaceuticamente aceitável da mesma. Mais especificamente, a presente invenção refere-se a uma composição farmacêutica capaz de controlar facilmente o padrão de dissolução de uma quantidade eficaz de lacosamida ou um sal farmaceuticamente aceitável da mesma.
BR112015025058-0A 2013-04-02 2014-03-24 Composição farmacêutica do tipo matriz contendo lacosamida BR112015025058B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2013-0035989 2013-04-02
KR1020130035989A KR101732731B1 (ko) 2013-04-02 2013-04-02 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물
PCT/KR2014/002454 WO2014163314A1 (ko) 2013-04-02 2014-03-24 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물

Publications (3)

Publication Number Publication Date
BR112015025058A2 BR112015025058A2 (pt) 2017-07-18
BR112015025058A8 true BR112015025058A8 (pt) 2023-01-03
BR112015025058B1 BR112015025058B1 (pt) 2023-11-21

Family

ID=51658558

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025058-0A BR112015025058B1 (pt) 2013-04-02 2014-03-24 Composição farmacêutica do tipo matriz contendo lacosamida

Country Status (4)

Country Link
KR (1) KR101732731B1 (pt)
CN (1) CN105228608B (pt)
BR (1) BR112015025058B1 (pt)
WO (1) WO2014163314A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104784134B (zh) * 2015-04-12 2018-05-29 石家庄四药有限公司 一种拉科酰胺固体制剂及其制备方法
MA43532A (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals Inc Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
KR102544141B1 (ko) * 2016-09-29 2023-06-16 에스케이케미칼 주식회사 라코사미드 서방성 제제
KR102083241B1 (ko) 2018-02-14 2020-03-02 환인제약 주식회사 라코사미드를 함유하는 약제학적 서방성 조성물
CN109010301B (zh) * 2018-09-05 2021-01-26 上海上药第一生化药业有限公司 一种拉考沙胺晶型ii片剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011008298A2 (en) * 2009-07-16 2011-01-20 Nectid, Inc. Novel axomadol dosage forms
WO2011055385A1 (en) * 2009-11-03 2011-05-12 Lupin Limited Modified release formulation of lacosamide
WO2011101863A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
MX2013005974A (es) 2010-12-02 2013-07-29 Ucb Pharma Gmbh Formulacion de lacosamida de administracion una vez al dia.
EP2468261A1 (en) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide

Also Published As

Publication number Publication date
BR112015025058A2 (pt) 2017-07-18
KR20140120191A (ko) 2014-10-13
WO2014163314A1 (ko) 2014-10-09
CN105228608B (zh) 2019-05-28
BR112015025058B1 (pt) 2023-11-21
KR101732731B1 (ko) 2017-05-08
CN105228608A (zh) 2016-01-06

Similar Documents

Publication Publication Date Title
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
BR112015025058A8 (pt) Composição farmacêutica do tipo matriz contendo lacosamida
BR112016015851A2 (pt) Formulações farmacêuticas estabilizadas de insulina aspart
BR112015011430A2 (pt) composição para liberação imediata e prolongada
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
BR112013019522A2 (pt) dissialil lacto-n-tetraose (dslnt) ou as variantes, os isômeros, os análogos e os derivados da mesma para prevenir ou inibir doença do intestino
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112017022846A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de dois fármacos de partículas diferentes
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112016013754A2 (pt) Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
UY35209A (es) Compuestos tricíclicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIOINNOTIS CO., LTD. (KR)

B25A Requested transfer of rights approved

Owner name: HYUNDAI PHARM CO., LTD. (KR)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/2014, OBSERVADAS AS CONDICOES LEGAIS